Revenue
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $135,000 | $0 | — | — |
| Gross profit | $1.2M | $135,000 | $0 | — | — |
| Research & development | $7.5M | $9.1M | $6.0M | $2.5M | $2.8M |
| Operating expenses | $13.4M | $18.0M | $14.2M | $11.6M | $4.4M |
| Operating income | −$12.2M | −$17.8M | −$14.2M | −$11.6M | −$4.4M |
| Net income | −$12.2M | −$24.8M | −$26.2M | −$12.2M | −$4.6M |
| Basic EPSper diluted share | -$5.86 | -$66.33 | -$30.26 | -$1.48 | -$0.63 |
| Diluted EPSper diluted share | — | -$6.63 | -$30.26 | -$1.48 | -$0.63 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 19, 2025Form 4 | Baird Jennifer ADirector | BuyCommon Stock | 4.2K | $0.24 | $1.0K | 36.2K |
| Dec 9, 2025Form 4 | Messinger MichaelChief Financial Officer | BuyCommon Stock | 14.5K | $0.35 | $5.1K | 17.5K |
| Aug 27, 2025Form 4 | Van Heel KennethDirector | BuyCommon Stock, par value $0.0001 per share | 10.0K | $0.86 | $8.6K | 49.4K |
| Aug 26, 2025Form 4 | Van Heel KennethDirector | BuyCommon Stock, par value $0.0001 per share | 25.0K | $0.89 | $22.3K | 39.4K |
| Aug 22, 2025Form 4 | Chung KevinChief Medical Officer | BuyCommon Stock, par value $0.0001 per share | 10.0K | $0.80 | $8.0K | 58.2K |